Which medications are considered investigational and not recommended for general use in patients with frontotemporal dementia (FTD)?

Updated: Jun 14, 2018
  • Author: Howard S Kirshner, MD; Chief Editor: Jasvinder Chawla, MD, MBA  more...
  • Print


All of the pharmacologic treatments listed below must be considered investigational and not recommended for general use.

Dopaminergic drugs have been tested in patients with transcortical motor aphasia secondary to strokes. Anecdotal experience with dopamine agonist agents such as bromocriptine (Parlodel), pergolide (Permax), pramipexole (Mirapex), and ropinirole (Requip) has been unimpressive. Bromocriptine and pergolide are no longer available.

Stimulant drugs such as amphetamines and modafinil (Provigil) may benefit patients with frontal lobe syndromes. Large, randomized, double-blind studies are lacking. There is concern that the stimulant drugs might worsen behavior in patients with behavioral variant FTD.

As stated previously, the last few years have witnessed major breakthroughs in the understanding of the molecular genetics of these disorders, and we hope that treatment breakthroughs will follow.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!